1. "Hematologic Malignancies, Division of"
Formats
  1. Meeting Abstract (6210)
  2. Journal Article (5696)
  3. Review (405)
  4. Book Section (186)
  5. Editorial (186)
  6. Research Letter (169)
  7. Guidelines (86)
  8. Conference Paper (65)
  9. Correspondence (58)
  10. Miscellaneous (17)
  11. Book Whole (9)
Groups
  1. Hematologic Malignancies, Division of (13087)
  2. Department of Medicine (13003)
  3. Center for Hematologic Malignancies (10394)
  4. GSK Faculty (4421)
  5. Adult Leukemia (3582)
  6. Bone Marrow Transplant (2776)

More Groups

People
  1. Sergio Giralt (1050)
  2. Miguel-Angel Perales (913)
  3. Ross Levine (774)
  4. Andrew Zelenetz (767)
  5. Martin Tallman (649)
  6. Steven Horwitz (645)

More People

Years
  1. 2025 (203)
  2. 2024 (670)
  3. 2023 (1038)
  4. 2022 (964)
  5. 2021 (875)
  6. 2020 (936)

More Years

Publications
  1. Blood (3371)
  2. Journal of Clinical Oncology (1214)
  3. Biology of Blood and Marrow Transplantation (596)
  4. Clinical Lymphoma, Myeloma and Leukemia (328)
  5. Haematologica (289)
  6. Bone Marrow Transplantation (238)

More Publications

Publishers
  1. American Society of Hematology (3638)
  2. Elsevier Inc. (1609)
  3. American Society of Clinical Oncology (1266)
  4. Nature Publishing Group (994)
  5. American Association for Cancer Research (637)
  6. Wiley Blackwell (430)

More Publishers

Results (13087)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Characteristics and outcomes of ibrutinib-associated musculoskeletal toxities in CLL patients
    Meeting Abstract

    Rhodes, J.; Mato, A. R.; Winchell, N.; Kennard, K.; Gerson, J. N.; Landsburg, D. J.; Nasta, S. D.; Svoboda, J.; Schuster, S. J.
    Blood (2018)

    Fulltext@MSK | Save
  • Real-world treatment patterns among a contemporary cohort of commercially insured mantle cell lymphoma patients in the United States
    Meeting Abstract

    Roeker, L. E.; Kabadi, S.; Burudpakdee, C.; Near, A.; Wada, K.; Mato, A. R.
    Blood (2018)

    Fulltext@MSK | Save
  • Efficacy of combined ruxolitinib and decitabine in patients with accelerated and blast-phase myeloproliferative neoplasms: Results of a phase II study (MPN-RC109 trial)
    Meeting Abstract

    Rampal, R. K.; Mascarenhas, J.; Kosiorek, H. E.; Bhave, R.; Hexner, E. O.; Wang, E. S.; Gerds, A. T.; Heaney, M. L.; Abboud, C. N.; Kremyanskaya, M.; more...
    Blood (2018)

    Fulltext@MSK | Save
  • Adoptive therapy with EBV-specific T cells for treatment of CNS EBV post-transplant lymphoproliferative disease arising after hematopoietic stem cell transplant or solid organ transplant
    Meeting Abstract

    Prockop, S.; Suser, S.; Doubrovina, E.; Castro-Malaspina, H. R.; Papadopoulos, E. B.; Sauter, C. S.; Young, J. W.; Szenes, V.; Slocum, A.; Baroudy, K.; more...
    Blood (2018)

    Fulltext@MSK | Save
  • V(D)J sequence capture for DNA-based minimal residual disease detection in multiple myeloma
    Meeting Abstract

    Rustad, E. H.; Hultcrantz, M.; Yellapantula, V. D.; Akhlaghi, T.; Ho, C.; Arcila, M. E.; Roshal, M.; Patel, A.; Devlin, S. M.; Jacobsen, A.; more...
    Blood (2018)

    Fulltext@MSK | Save
  • Treatment outcomes in monoclonal immunoglobulin deposition disease (MIDD): A two center experience
    Meeting Abstract

    Pianko, M. J.; Tiutan, T.; Flynn, J.; Devlin, S. M.; Jaffer-Sathick, I.; Rossi, A. C.; Salvatore, S. P.; Landau, H. J.; Lendvai, N.; Smith, E. L.; more...
    Blood (2018)

    Fulltext@MSK | Save
  • A high degree of engrafting unit-recipient HLA-allele mismatch is not associated with an increased risk of transplant-related mortality (TRM) or inferior progression-free survival (PFS) after double unit cord blood (CB) transplantation (dCBT) in adults with hematologic malignancies
    Meeting Abstract

    Politikos, I.; Devlin, S. M.; Maloy, M.; Mazis, C.; Naputo, K.; Afuye, A. O.; Scaradavou, A.; Avecilla, S. T.; Castro-Malaspina, H. R.; Cho, C.; more...
    Blood (2018)

    Fulltext@MSK | Save
  • Intestinal microbiota composition is associated with minimal residual disease negativity in patients with multiple myeloma
    Meeting Abstract

    Pianko, M. J.; Devlin, S. M.; Littmann, E. R.; Chansakul, A.; Mastey, D.; Salcedo, M.; Fontana, E.; Ling, L. L.; Tavitian, E.; Slingerland, J. B.; more...
    Blood (2018)

    Fulltext@MSK | Save
  • Comparison of costs and health care resource utilization (HRU) in chronic lymphocytic leukemia (CLL) patients treated with venetoclax (VEN) or chemotherapy (CT)/chemoimmunotherapy (CIT)
    Meeting Abstract

    Nabhan, C.; Mato, A. R.; Kish, J. K.; Nero, D.
    Blood (2018)

    Fulltext@MSK | Save
  • Cost-effectiveness comparison between ibrutinib, chemotherapy, and chemoimmunotherapy in front-line treatment of chronic lymphocytic leukemia (CLL)
    Meeting Abstract

    Nabhan, C.; Nero, D.; Lee, C. H.; Kish, J. K.; Mato, A. R.
    Blood (2018)

    Fulltext@MSK | Save